Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral IMOD plus antiretroviral therapy in adults with HIV infection
IRCT20180610040037N5Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of IMOD in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Complete blood count, Alkaline phosphatase and 7 more. Started Jul 2023; status: completed.
02
Drugs
IMOD
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on IRCT20180610040037N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180610040037N5.